Nicolas Gordon

Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses

Jung Min Lee, John L. Hays, Christina M. Annunziata et al. · JNCI Journal of the National Cancer Institute · 2014 · 183 citations · Full text

Medicine, Oncology, Pharmacology +14

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair

Ayesha A. Shafi, Christopher McNair, Jennifer J. McCann et al. · Nature Communications · 2021 · 131 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease

Amy C. Mandigo, Wei Yuan, Kexin Xu et al. · Cancer Discovery · 2021 · 98 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

PARP‐1 regulates DNA repair factor availability

Matthew J. Schiewer, Amy C. Mandigo, Nicolas Gordon et al. · EMBO Molecular Medicine · 2018 · 79 citations · Full text

Medicine, Cancer Biology, Oncology +14

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Jung Min Lee, Cody J. Peer, Minshu Yu et al. · Clinical Cancer Research · 2016 · 59 citations · Full text

Medicine, Oncology, Pharmacology +16